Voyager Therapeutics Inc (VYGR) is a Healthcare · Biotechnology company listed on NASDAQ. Price $3.06 (+0.66%), Market cap $0.21B, 52-week low–high $2.73 ~ $5.33.
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease. The company also provides research program for the treatment of Huntington's disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neurological disease; and develops selective small molecules for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia with TDP-43 pathology. The company has collaboration and
Financial statements, price targets, institutional (13F) holdings and related news for Voyager Therapeutics Inc are updated in real time on BlackAll Trade.
Voyager Therapeutics Inc trades at $3.06 (+0.66%). Real-time quotes and charts are available on BlackAll Trade.
Voyager Therapeutics Inc has a market cap of about $0.21B.
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523,